BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment
Nov 23, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for glioblastoma multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at the recently held H.C. Wainwright 24th Annual Global Investment Conference, this focus is driven by a significant unmet need, especially given that recurrent GBM does not have ‘an approved therapy anywhere in the world,’” a recent article reads. “With the survival rate and mortality statistics for GBM remaining virtually unchanged for decades, according to the National Brain Tumor Society, CNS Pharmaceuticals is working hard to find a solution. The company is relying on Berubicin, a novel anthracycline whose mechanism of action is inhibiting the topoisomerase II enzyme that causes cell replication and is abundantly found in tumor cells. CNS Pharmaceuticals has observed that the drug, which appears, based on limited clinical data, to cross the blood-brain barrier, is selectively absorbed in cancerous cells and tissue in the brain.”
To view the full article, visit https://ibn.fm/7NkMW
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
More News
SC initiative gives support to grassroots lawyers
MANILA, Philippines — The Supreme Court is formally extending support to public interest lawyers and organizations to help them in their missions while promoting grassroots lawyering as a viable career path. The Supreme Court on Friday released rules promulgated on Aug. 26 for the formal recognition of organizations and legal practitioners devoted to developmental and
5 heat-related ailments may also be compensated – ECC
MANILA, Philippines — Fainting, heat rash and kidney injury are among five additional heat-related conditions that may qualify workers for compensation under expanded guidelines issued by the Employees’ Compensation Commission (ECC) amid the looming threat of El Niño. “We came out with a resolution that reiterates the coverage of heat-related diseases while also recognizing the
4 PAF pilots killed in Batangas crash
MANILA, Philippines — Four Philippine Air Force (PAF) pilots were killed after two SF-260 aircraft crashed during a training flight in Batangas on Friday, the Air Force confirmed on Saturday. The PAF has described the incident as an “aviation accident” and could not immediately confirm if what had happened was a collision. Both aircraft went
Tesda chief denies P5-M ‘allocation’ for Lacson
MANILA, Philippines — The chief of the Technical Education and Skills Development Authority (Tesda) denied authorizing a P5-million allocation for Sen. Panfilo “Ping” Lacson. “As Tesda Secretary, I did not authorize anyone to offer any allocation or one amounting to P5 million to Senator Ping Lacson,” Tesda Director-General Jose Francisco “Kiko” Benitez said in a
2 Coast Guard personnel slain in Cotabato City shooting
MANILA, Philippines — Two Philippine Coast Guard (PCG) personnel have died following a shooting incident in Cotabato City, the agency confirmed as it mourned their deaths and vowed to pursue justice. In a statement on Saturday, the PCG identified the fatalities as Seaman First Class Reniel Agpalo and Seaman Second Class Louther Jhon Vitor, both
Higaonon youth of Agusan del Sur turns coffee waste into cascara tea
SAN FRANCISCO, AGUSAN DEL SUR, Philippines — For the past four decades, the coffee groves tended by the indigenous Higaonon tribe in Sitio San Jose, Barangay Maasin, in Esperanza town, Agusan del Sur, yielded a steady harvest of cherry beans for tribal communities in the area. However, the steady dose of caffeine these coffee plants
This week’s milestones: Oct. 25 to Oct. 31
Oct. 26, 1521 The remaining crew of the expedition once led by the Portuguese explorer Ferdinand Magellan dropped anchor at “Biraham Batulach,” known today as Barangay Batulaki, to take shelter from a violent storm. In the detailed account of the voyage, Antonio Pigafetta, a Venetian scholar and explorer, also wrote that Sebastian el Cano had
Before the Philippines even had a name, it had gold
“When you look at this gold jewelry, you realize that once upon a time we had a golden age. It gives you a sense of what was pre-colonial culture,” historian Ambeth Ocampo tells Rappler
/file/attachments/orphans/453234432234324_895682.png)
LFL urges AG to order murder probe into custodial death, seeks Bukit Aman takeover
Lawyers cite alleged internal injuries and question police account of cause of death.
Over October announces departure of rhythm guitarist Anton Rodriguez
Rhythm guitarist Anton Rodriguez will no longer be part of Over October.
Obama unloads on Trump while stumping for Democrats ahead of midterms
Obama frames the November 3 vote as a 'circuit breaker' to 'at least rein in some of the foolishness' of Trump's presidency
How Manny Pacquiao impacted UFC’s Aaron Pico
‘His fights were never boring,’ says mixed martial artist Aaron Pico of Manny Pacquiao. ‘That’s what I’m trying to do, too, here in the UFC.’
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.